Poly(ADP-Ribose) Polymerase Inhibition Reduces Reperfusion Injury After Heart Transplantation

Abstract

Abstract-The aim of the present study was to investigate the effects of the novel poly(ADP-ribose) polymerase (PARP) inhibitor PJ34 (N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide) on myocardial and endothelial function after hypothermic ischemia and reperfusion in a heterotopic rat heart transplantation model. After a 1-hour ischemic preservation, reperfusion was started either after application of placebo or PJ34 (3 mg/kg). The assessment of left ventricular pressure-volume relations, total coronary blood flow, endothelial function, myocardial high energy phosphates, and histological analysis were performed at 1 and 24 hours of reperfusion. After 1 hour, myocardial contractility and relaxation, coronary blood flow, and endothelial function were significantly improved and myocardial high energy phosphate content was preserved in the PJ34-treated animals. Improved transplant function was also seen with treatment with another, structurally different PARP inhibitor, 5-aminoisoquinoline. The PARP inhibitors did not affect baseline cardiac function. Immunohistological staining confirmed that PJ34 prevented the activation of PARP in the transplanted hearts. The activation of P-selectin and ICAM-1 was significantly elevated in the vehicle-treated heart transplantation group. Thus, pharmacological PARP inhibition reduces reperfusion injury after heart transplantation due to prevention of energy depletion and downregulation of adhesion molecules and exerts a beneficial effect against reperfusion-induced graft coronary endothelial dysfunction. (Circ Res. 2002;90:100-106.)Key Words: transplantation Ⅲ reperfusion injury Ⅲ PARP inhibition Ⅲ endothelial function Ⅲ rat I schemia/reperfusion injury is a common condition during cardiac surgery. Myocardial performance within the first hours after the surgical procedure determines the patient's state not only during the postoperative period but also in the long-term outcome, especially after heart transplantation when an extended time of ischemia is followed by reperfusion. Most studies about the effects of myocardial ischemia and reperfusion focus on myocardial injury and the recovery of contractile function. It is now appreciated that the survival of the heart as a whole depends in part on the ability of the microcirculation to deliver and distribute blood flow adequately during reperfusion. Recent studies show the importance of protecting the microvasculature to attenuate reperfusion injury. 1 Therefore, novel therapeutic strategies concentrate on management modalities that prevent both myocardial and endothelial injury during reperfusion.Ischemia/reperfusion injury initiates a pathophysiological cascade including an inflammatory response with liberation of cytokines and free radicals. A recently discovered mechanism of cell injury, the poly-ADP-ribose polymerase (PARP) pathway (see Sims et al 2 and Schraufstter et al 3 ;overview in Szabó 4 ) is involved in the pathogenesis of various forms of ischemia/reperfusion injury. In 1997, Thiemermann et al 5 and Zing...

Poly(ADP-ribose) polymerase-1 in high glucose-induced epithelial-mesenchymal transition during peritoneal fibrosis

“…PARP-1 is a 116-kDa protein that consists of three main domains: the N-terminal DNA-binding domain containing two zinc fingers, the automodification domain, and the C-terminal catalytic domain. Over-activation of PARP by reactive oxygen and nitrogen intermediates represents a pathogenetic factor in various forms of inflammation, myocardial reperfusion injury, heart transplantation, heart failure, stroke, circulatory shock, and autoimmune β-cell destruction associated with diabetes mellitus (11)(12)(13)(14). Activation of PARP and the beneficial effect of various PARP inhibitors have been demonstrated in various forms of endothelial dysfunction, such as those associated with circulatory shock, hypertension, atherosclerosis, pre-eclampsia, and aging (15,16).…”

Renal Parenchymal Hypoxia, Hypoxia Adaptation, and the Pathogenesis of Radiocontrast Nephropathy

“…Thus, a vicious circle of hypoxia, free radical formation, and further hypoxic injury may be activated after radiocontrast exposure. Activation of highenergy-consuming reparative processes such as poly-(ADP-ribose) polymerase (PARP) may further aggravate intracellular energy store depletion and subsequent endothelial dysfunction, further augmenting regional hypoxic injury (40).…”

Poly(ADP‐ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions

“…43 The size of myocardial infarcts could be significantly reduced by abrogating PARP activity using the inhibitor PJ34 before the onset of reperfusion after a 1 hour ischaemia. 44 When administering the PARP inhibitor 5-aminoisoquinolinone (5-AIQ) to rats 5 min prior to the onset of liver ischaemia, a reduction in liver injury was observed as judged by reduced serum levels of transaminases, lactate dehydrogenase, gamma-glutamyl transferase and less staining for intercellular adhesion molecule-1 (ICAM-1) in liver sections. 45 Intraperitoneal administration of PARP inhibitors after ischaemia-reperfusion injury of the kidney accelerated the recovery of normal renal function, as assessed by monitoring the levels of plasma creatinine and blood urea nitrogen during 6 days after the ischaemic insult.…”